Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Cancer Immunol Res. 2014 Nov 4;3(2):136–148. doi: 10.1158/2326-6066.CIR-14-0036

Figure 1. Tasquinimod improves immunotherapy in CR Myc-CaP prostate cancer and B16 melanoma models.

Figure 1

A. Mice were inoculated s.c. with CR Myc-CaP cells. When the tumors reached an average size of 25 mm2, mice were treated with vehicle, survivin, tasquinimod or the combination of survivin and tasquinimod. Left panel shows tumor growth curves by serial caliper measurements. Right panel shows tumor weights at the endpoint. B. Mice were inoculated s.c. with B16-h5T4 cells and treatment with tasquinimod was initiated the day after inoculation and continued throughout the experiment. The TTS protein 5T4Fab-SEA (25μg/kg) was given as daily i.v. injections on days 3 to 6. Left panel shows tumor growth curves by serial caliper measurements. Right panel shows end of treatment tumor weights. The experiments were repeated at least twice. Results from one representative experiment are shown. (* p<0.05; ** p<0.01; *** p<0.001; Mann-Whitney U. Error bars indicate s.e.m.)